Leaps by Bayer and Norrsken Foundation share a commitment to invest in transformative ideas that could change people’s live for the better. Leaps tackles seemingly impossible challenges through significant and sustained investments in disruptive biotechnologies—investments that break boundaries in scale, risk, collaboration, and mission. We learn from partners like Norrsken who work across a range of industries, opening us to diverse ideas and new approaches. We admire the multifaceted approach Norrsken takes to empowering the impact entrepreneurship ecosystem—from bold investments to community-building to thought leadership.Become a partner
"Norrsken is proud to join forces with Leaps by Bayer to tackle the most pressing global health and food challenges facing humanity."
- Erik Engellau-Nisslon, Norrsken CEo
Leaps by Bayer has invested nearly $1B in companies working to shift key paradigms in health and agriculture, each investment aims to solve one of 10 huge challenges or ‘leaps’. In 2019, Leaps made 14 new investments, bringing our portfolio to 32 companies.
We recognize that breakthroughs in biotech can raise important ethical questions that can’t be answered by scientists and investors alone. Through programs like Leaps Talks and leapsmag, we collaborate with partners worldwide to engage others in industry, academia, leaders, and civil society in this critical dialogue.
Leaps has partnered with Norrsken to bring our Leaps Talk series to life. The 3rd Leaps Talk took place at the Norrsken House Stockholm in October 2019, entitled ‘Hacking Humans: A unique conversation about gene-editing and AI’ featuring Jamie Metzl, Max Tegmark and moderator Elaine Grunewald. These brilliant thinkers engaged a packed audience to discuss how the rapid development of genetic engineering and artificial intelligence needs to be guided by standards, ethics, and shared values, in order to achieve breakthroughs safely. The full talk and excerpts can be viewed here.